Table of Content

1 Market: Industry Outlook
1.1 Market: Industry Outlook
1.1.1 Trends: Current and Future Impact Assessment
1.1.1.1 Growing Collaborations and Partnerships among Market Players
1.1.1.2 Increasing Fundings Initiatives
1.1.2 Research and Development Review
1.1.2.1 Patent Filing Trend
1.1.2.1.1 By Country
1.1.2.1.2 By Year
1.1.3 Regulatory Requirements
1.1.3.1 Regulatory Scenario in the U.S.
1.1.3.2 Regulatory Scenario in the European Union
1.1.3.3 Regulatory Scenario in Asia-Pacific
1.1.4 Pipeline Analysis
1.1.5 Pricing Analysis
1.1.6 Market Dynamics
1.1.6.1 Impact Analysis
1.1.6.2 Market Drivers
1.1.6.2.1 Increasing Incidence of Cancer Leading to Increased Demand for Early Detection
1.1.6.2.2 Rising Adoption of Liquid Biopsy for Cancer Screening
1.1.6.2.3 Raising Awareness among the Population about Early Detection of Cancer Leading to Higher Survival Chances and Better Treatment
1.1.6.3 Market Restraints
1.1.6.3.1 High Cost of Multi-Cancer Early Detection Tests
1.1.6.4 Market Opportunities
1.1.6.4.1 Discovery of New Biomarkers
1.1.6.4.2 Integration of Artificial Intelligence (AI) in Cancer Screening

2 Global Multi-Cancer Early Detection Market, by Technology
2.1 Next-Generation Sequencing (NGS)
2.2 Polymerase Chain Reaction (PCR)
2.3 Other Technologies

3 Global Multi-Cancer Early Detection Market, by Sample Type
3.1 Blood
3.2 Saliva and Buccal Swab
3.3 Others

4 Global Multi-Cancer Early Detection Market, by End User
4.1 Hospital
4.2 Research Institutes
4.3 Others

5 Global Multi-Cancer Early Detection Market, by Region
5.1 Regional Summary
5.2 North America
5.2.1 Regional Overview
5.2.2 Business Drivers
5.2.3 Business Challenges
5.2.4 Market Sizing and Forecast
5.2.4.1 U.S.
5.2.4.2 Canada
5.3 Europe
5.3.1 Regional Overview
5.3.2 Business Drivers
5.3.3 Business Challenges
5.3.4 Market Sizing and Forecast
5.3.4.1 Germany
5.3.4.2 U.K.
5.3.4.3 France
5.3.4.4 Italy
5.3.4.5 Spain
5.3.4.6 Rest-of-Europe
5.4 Asia-Pacific
5.4.1 Regional Overview
5.4.2 Business Drivers
5.4.3 Business Challenges
5.4.4 Market Sizing and Forecast
5.4.4.1 Japan
5.4.4.2 China
5.4.4.3 India
5.4.4.4 Rest-of-Asia-Pacific
5.5 Rest-of-the-World
5.5.1 Regional Overview
5.5.2 Market Sizing and Forecast

6 Markets: Competitive Landscape and Company Profiles
6.1 Competitive Landscape
6.1.1 Key Strategies and Development
6.1.2 Partnerships, Alliances, and Business Expansions
6.1.3 Funding Activities
6.1.4 Other Initiatives
6.2 Company Profiles
6.2.1 Burning Rock Biotech Limited
6.2.1.1 Overview
6.2.1.2 Top Products/Services
6.2.1.3 Top Competitors
6.2.1.4 Target Customers/End Users
6.2.1.5 Key Personnel
6.2.1.6 Analyst View
6.2.2 Exact Sciences Corporation
6.2.2.1 Overview
6.2.2.2 Top Products/Services
6.2.2.3 Top Competitors
6.2.2.4 Target Customers/End Users
6.2.2.5 Key Personnel
6.2.2.6 Analyst View
6.2.3 Freenome Holding, Inc.
6.2.3.1 Overview
6.2.3.2 Top Products/Services
6.2.3.3 Top Competitors
6.2.3.4 Target Customers/End Users
6.2.3.5 Key Personnel
6.2.3.6 Analyst View
6.2.4 GRAIL, Inc.
6.2.4.1 Overview
6.2.4.2 Top Products/Services
6.2.4.3 Top Competitors
6.2.4.4 Target Customers/End Users
6.2.4.5 Key Personnel
6.2.4.6 Analyst View
6.2.5 Guardant Health
6.2.5.1 Overview
6.2.5.2 Top Products/Services
6.2.5.3 Top Competitors
6.2.5.4 Target Customers/End Users
6.2.5.5 Key Personnel
6.2.5.6 Analyst View
6.2.6 Natera, Inc.
6.2.6.1 Overview
6.2.6.2 Top Products/Services
6.2.6.3 Top Competitors
6.2.6.4 Target Customers/End Users
6.2.6.5 Key Personnel
6.2.6.6 Analyst View
6.2.7 Prenetics Global Limited
6.2.7.1 Overview
6.2.7.2 Top Products/Services
6.2.7.3 Top Competitors
6.2.7.4 Target Customers/End Users
6.2.7.5 Key Personnel
6.2.7.6 Analyst View
6.2.8 Lucence Health Inc.
6.2.8.1 Overview
6.2.8.2 Top Products/Services
6.2.8.3 Top Competitors
6.2.8.4 Target Customers/End Users
6.2.8.5 Key Personnel
6.2.8.6 Analyst View
6.2.9 Laboratory Corporation of America Holdings
6.2.9.1 Overview
6.2.9.2 Top Products/Services
6.2.9.3 Top Competitors
6.2.9.4 Target Customers/End Users
6.2.9.5 Key Personnel
6.2.9.6 Analyst View
6.2.10 Precision Epigenomics
6.2.10.1 Overview
6.2.10.2 Top Products/Services
6.2.10.3 Top Competitors
6.2.10.4 Target Customers/End Users
6.2.10.5 Key Personnel
6.2.10.6 Analyst View
6.2.11 20/20 Gene Systems
6.2.11.1 Overview
6.2.11.2 Top Products/Services
6.2.11.3 Top Competitors
6.2.11.4 Target Customers/End Users
6.2.11.5 Key Personnel
6.2.11.6 Analyst View
6.2.12 Ajinomoto Co., Inc.
6.2.12.1 Overview
6.2.12.2 Top Products/Services
6.2.12.3 Top Competitors
6.2.12.4 Target Customers/End Users
6.2.12.5 Key Personnel
6.2.12.6 Analyst View
6.2.13 CENTOGENE N.V.
6.2.13.1 Overview
6.2.13.2 Top Products/Services
6.2.13.3 Top Competitors
6.2.13.4 Target Customers/End Users
6.2.13.5 Key Personnel
6.2.13.6 Analyst View

7 Research Methodology
7.1 Data Sources
7.1.1 Primary Data Sources
7.1.2 Secondary Data Sources
7.1.3 Data Triangulation
7.2 Market Estimation and Forecast

List of Figures
Figure 1: Global Multi-Cancer Early Detection Market (by Technology), $Million, 2023 and 2034
Figure 2: Global Multi-Cancer Early Detection Market (by Sample Type), $Million, 2023 and 2034
Figure 3: Global Multi-Cancer Early Detection Market (by End User), $Million, 2023 and 2034
Figure 4: Key Events to Keep Track of in the Global Multi-Cancer Early Detection Market
Figure 5: Number of Patents in Multi-Cancer Early Detection Market (by Country), January 2021-December 2024
Figure 6: Number of Patents in Multi-Cancer Early Detection Market (by Year), January 2021-December 2024
Figure 7: Global Incidence of Cancer, Million, 2022-2025
Figure 8: North America Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 9: U.S. Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 10: Canada Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 11: Europe Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 12: Germany Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 13: U.K. Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 14: France Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 15: Italy Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 16: Spain Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 17: Rest-of-Europe Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 18: Asia-Pacific Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 19: Japan Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 20: China Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 21: India Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 22: Rest-of-Asia-Pacific Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 23: Rest-of-the-World Multi-Cancer Early Detection Market, $Million, 2022-2034
Figure 24: Share of Strategic Initiatives, January 2022-January 2025
Figure 25: Strategic Initiatives (by Year), January 2022-January 2025
Figure 26: Partnerships, Alliances, and Business Expansions, January 2022-January 2025
Figure 27: Funding Activities, January 2022-January 2025
Figure 28: Other, January 2022-January 2025
Figure 29: Data Triangulation
Figure 30: Top-Down and Bottom-Up Approach
Figure 31: Assumptions and Limitations

List of Tables
Table 1: Market Snapshot
Table 2: Opportunities across Region
Table 3: Key Trends, Global Multi-Cancer Early Detection Market
Table 4: Recent Collaboration and Partnerships Among Market Players, 2024
Table 5: Some of the Funding Initiatives in the Global Multi-Cancer Early Detection Market
Table 6: Some of the Pipeline Products in the Global Multi-cancer Early Detection Market
Table 7: Average Price for Multi-Cancer Early Detection Products
Table 8: Impact Analysis of Market Navigating Factors, 2022-2034
Table 9: Global Multi-Cancer Early Detection Market (by Technology), $Million, 2022-2034
Table 10: Global Multi-Cancer Early Detection Market (by Sample Type), $Million, 2022-2034
Table 11: Global Multi-Cancer Early Detection Market (by End User), $Million, 2022-2034
Table 12: Global Multi-Cancer Early Detection Market (by Region), $Million, 2022-2034